- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Dupilumab, Matching Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 48
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 129
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
- Conditions
- Healthy
- Interventions
- SAR231893 (REGN668) DP1, SAR231893 (REGN668) DP2
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Asthma
- Interventions
- dupilumab, Matching Placebo, ICS/LABA
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 51
- States / cities
- Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more
- Conditions
- Asthma
- Interventions
- Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 50
- States / cities
- Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab, Placebo (for Dupilumab)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Allergic Rhinitis
- Interventions
- Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Mountain View, California • Walnut Creek, California + 9 more
- Conditions
- Asthma
- Interventions
- Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Healthy Volunteer
- Interventions
- Dupilumab (SAR231893)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Saint Paul, Minnesota • Springfield, Missouri
- Conditions
- Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
- Conditions
- Dermatitis
- Interventions
- REGN668
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Riverside, California • Miami, Florida + 7 more
- Conditions
- Conjunctivitis, Atopic Dermatitis
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Irvine, California • Palo Alto, California • Pasadena, California + 12 more
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 18
- States / cities
- Long Beach, California • Orange, California • San Diego, California + 15 more
- Conditions
- Nasal Polyps
- Interventions
- Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Rolling Hills Estates, California • Denver, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Asthma
- Interventions
- DUPIXENT®
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 63 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 39 more
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Dupilumab, Placebo, Background treatment
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • New York, New York • Dallas, Texas